4P004 is a novel first-in-class drug candidate addressing a high unmet medical need that is the absence of a curative treatment for osteoarthritis.
Through the development of 4P004, we hope to bring a solution to improve quality of life for the millions of people suffering from osteoarthritis worldwide.
Cartilage protection/regeneration: 4P004 blocks the expression of degradative enzymes. In an experimental OA surgical model, 4P004 increases medial cartilage repair. Moreover, 4P004 increases the number of proliferating chondrocytes clusters, revealing not only a decrease in cartilage degradation, but also cartilage regeneration